Roble Belko & Company’s BioMarin Pharmaceuticals BMRN Stock Holding History

Roble Belko & Company’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-205	Closed	-$17K	–	320
2020 Q1	$17K	Hold	205	–	–	0.01%	198
2019 Q4	$17K	Hold	205	–	–	﹤0.01%	229
2019 Q3	$14K	Hold	205	–	–	﹤0.01%	237
2019 Q2	$18K	Hold	205	–	–	0.01%	207
2019 Q1	$18K	Hold	205	–	–	0.01%	175
2018 Q4	$17K	Hold	205	–	–	0.01%	161
2018 Q3	$20K	Hold	205	–	–	0.01%	160
2018 Q2	$19K	Sell	205 -633	-76%	-$55.4K	0.01%	168
2018 Q1	$68K	Buy	838 +238	+40%	+$20.4K	0.03%	105
2017 Q4	$54K	Buy	+600	New	+$52.2K	0.02%	111
2017 Q2	–	Sell	-39	Closed	-$3K	–	304
2017 Q1	$3K	Hold	39	–	–	﹤0.01%	285
2016 Q4	$3K	Buy	+39	New	+$3.35K	﹤0.01%	303

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Roble Belko & Company's BMRN Position: Q2 2020 in Review

Roble Belko & Company sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2020, closing a stake of 205 shares — an estimated $17K sold.

Roble Belko & Company first reported a position in BMRN in Q4 2016 and held it in 12 quarters. The position peaked at $68K in Q1 2018. 528 funds tracked by Wall St. Rank hold BMRN as of Q2 2020.

Roble Belko & Company reported no remaining BioMarin Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
Roble Belko & Company sold 205 BioMarin Pharmaceuticals shares in Q2 2020, an estimated $17K.
Roble Belko & Company first reported a position in BioMarin Pharmaceuticals in Q4 2016 and held it in 12 quarters.
Roble Belko & Company's BioMarin Pharmaceuticals position peaked at $68K in Q1 2018.
528 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2020.

Based on Roble Belko & Company's 13F filing for Q2 2020, filed 10 Aug 2020.